Fumarate hydratase deficient renal cell carcinoma: Chromosomal numerical aberration analysis of 12 cases.


Journal

Annals of diagnostic pathology
ISSN: 1532-8198
Titre abrégé: Ann Diagn Pathol
Pays: United States
ID NLM: 9800503

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 22 01 2019
accepted: 08 02 2019
pubmed: 21 2 2019
medline: 31 10 2019
entrez: 21 2 2019
Statut: ppublish

Résumé

Hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma (HLRCC)/fumarate hydratase deficient renal cell carcinoma (FHRCC) is defined by molecular genetic changes (mutation/LOH in fumarate hydratase (FH) gene). We investigated chromosomal numerical aberration pattern (CNV) in FHRCC/HLRCC using array comparative genomic hybridization analysis and low pass whole genome sequencing. Genetic analysis was successfully completed in 12 tumors. Most common chromosomal aberrations detected were a complete or partial loss of chromosome 4 (5/12 cases), chromosome 15 (4/12 cases), and chromosomes 9, 13, and 14 (each in 3/12 cases), as well as a complete or partial gain of chromosome 17 (in 4/12 cases). No chromosomal losses or gains were detected in 4 cases. Copy number variation pattern in FHRCC/HLRCC appears to be highly variable and does not provide a useful diagnostic tool in identifying these cases. Immunohistochemical staining and especially molecular genetic evaluation of FH gene mutations/LOH remain the gold standard in identifying FHRCC/HLRCC.

Identifiants

pubmed: 30785029
pii: S1092-9134(19)30031-0
doi: 10.1016/j.anndiagpath.2019.02.008
pii:
doi:

Substances chimiques

Fumarate Hydratase EC 4.2.1.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

63-68

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Auteurs

Kristyna Pivovarcikova (K)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, University Hospital Plzen, Pilsen, Czech Republic.

Petr Martinek (P)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, University Hospital Plzen, Pilsen, Czech Republic.

Petr Grossmann (P)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, University Hospital Plzen, Pilsen, Czech Republic.

Kiril Trpkov (K)

Calgary Laboratory Services and University of Calgary, Calgary, AB, Canada.

Reza Alaghehbandan (R)

Department of Pathology, Faculty of Medicine, University of British Columbia, Royal Columbian Hospital, Vancouver, BC, Canada.

Cristina Magi-Galluzzi (C)

Department of Pathology, School of Medicine, University of Alabama, Birmingham, AL, USA.

Maria Pane Foix (M)

Department of Pathology, Bellvitge Biomedical Research Institut (IDIBELL), Bellvitge University Hospital, University of Barcelona School of Medicine, L'Hospitalet de Llobregat, Barcelona, Spain".

Enric Condom Mundo (E)

Department of Pathology, Bellvitge Biomedical Research Institut (IDIBELL), Bellvitge University Hospital, University of Barcelona School of Medicine, L'Hospitalet de Llobregat, Barcelona, Spain".

Daniel Berney (D)

Bart's Cancer Center, London, United Kingdom.

Anthony Gill (A)

Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research and University of Sydney, Sydney, NSW, Australia.

Boris Rychly (B)

Department of Pathology, Cytopathos, Bratislava, Slovakia.

Kvetoslava Michalova (K)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, University Hospital Plzen, Pilsen, Czech Republic.

Joanna Rogala (J)

Department of Pathology Regional Specialist Hospital, Wroclaw, Poland.

Tomas Pitra (T)

Department of Urology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.

Tamas Micsik (T)

1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.

Jiri Polivka (J)

Department of Histology and Embryology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.

Milan Hora (M)

Department of Urology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.

Ozlem Tanas Isikci (O)

Department of Pathology, Ankara Training and Research Hospital, Ankara, Turkey.

Sarka Skalova (S)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, University Hospital Plzen, Pilsen, Czech Republic.

Jana Mareckova (J)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, University Hospital Plzen, Pilsen, Czech Republic.

Michal Michal (M)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, University Hospital Plzen, Pilsen, Czech Republic.

Ondrej Hes (O)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, University Hospital Plzen, Pilsen, Czech Republic. Electronic address: hes@biopticka.cz.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH